四环医药(00460.HK)：轩悦宁(吡洛西利片)第三个适应症上市申请获得NMPA批准用于一线治疗HR+/HER2-晚期乳腺癌

Core Viewpoint - Four Ring Pharmaceutical's subsidiary, Xuan Zhu Biotechnology, has received approval from the National Medical Products Administration (NMPA) in China for the new indication of its innovative drug, Pyrotinib (brand name: Xuan Yue Ning®), for first-line treatment of HR+/HER2- advanced breast cancer, marking it as the first and only drug in China to cover all treatment lines for this cancer subtype [1][2]. Group 1: Company Developments - The approval of Pyrotinib's new indication significantly expands the patient coverage and enhances the clinical value and accessibility of the drug, providing strong support for future sales growth [1]. - Pyrotinib has now been approved for three indications in China, following its previous approvals for combination therapy with Fulvestrant and monotherapy [1]. Group 2: Industry Context - Breast cancer is the most commonly diagnosed malignant tumor among women globally, with new cases in China projected to rise from 322,200 in 2018 to 374,700 in 2024, and expected to reach 435,000 by 2032 [2]. - HR+/HER2- breast cancer is the most prevalent subtype in China, accounting for approximately 75% of cases, with about 30% of these diagnosed as advanced breast cancer [2]. - The market for CDK4/6 inhibitors combined with endocrine therapy for HR+/HER2- advanced breast cancer is expected to reach RMB 13 billion by 2032 [2]. Group 3: Clinical Research Insights - The approval for the new indication is based on data from the BRIGHT-3 study, a randomized, double-blind Phase III clinical trial conducted at 58 centers in China, assessing the efficacy and safety of Pyrotinib in combination with Letrozole or Anastrozole for first-line treatment of HR+/HER2- advanced breast cancer [3]. - The BRIGHT-3 study results indicated that the median progression-free survival (mPFS) for the Pyrotinib group has not yet been reached, suggesting a durable efficacy advantage, with a 47% reduction in the risk of disease progression or death compared to the control group [3]. - In the intention-to-treat population, the overall response rate (ORR) for the Pyrotinib group was 63.5%, significantly higher than the control group's 42.5%, with manageable safety profiles for common adverse events [3].